GH Research PLC Completes $111.2 Million Public Offering of Ordinary Shares

On April 30, 2026, GH Research PLC completed an underwritten public offering of 6,527,779 ordinary shares at a price of $18.00 per share. The offering, conducted pursuant to an underwriting agreement with Stifel, Nicolaus & Company and Cantor Fitzgerald & Co., resulted in estimated net proceeds of approximately $111.2 million after deducting underwriting discounts, commissions, and estimated offering expenses. The Company intends to utilize the net proceeds to strategically invest in the research, clinical, and technical development of its current and/or additional product candidates both in the U.S. and internationally. Furthermore, funds are earmarked for pre-commercialization activities, working capital, capital expenditures, and general corporate purposes. GH Research is a clinical-stage biopharmaceutical company focused on developing therapies for psychiatric and neurological disorders. The shares were offered under the company's existing shelf registration statement on Form F-3. In connection with the offering, the company issued a press release on April 29, 2026, announcing the pricing of the transaction.